Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis

Journal of Thrombosis and Thrombolysis

Volumn 7, Issue 3, 1999, Pages 301-306

  McClanahan, Thomas B ^a   Ignasiak, Diane P ^b   Juneau, Paul ^b   Finkle, Carolyn ^b   Winocour, Peter D ^b   Gallagher, Kim P ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

Antithrombotic; Direct thrombin inhibitor; Electrolytic injury; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; DEXTRO PHENYLALANYLPROLYL 5 AMINOVALERYL 5 AMINOVALERYLASPARTYLPHENYLALANYLGLUTAMYLPROLYLISOLEUCYLPROLYLLEUCINE; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL OCCLUSION; BOLUS INJECTION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOG; DRUG INFUSION; ELECTRIC CURRENT; FEMORAL VEIN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; STATISTICS; THROMBIN TIME; THROMBUS; VEIN BLOOD FLOW; VEIN INJURY; VEIN THROMBOSIS;

ANIMALS; ANIONS; BINDING SITES; BLEEDING TIME; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; FEMORAL VEIN; FIBRINOLYTIC AGENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; OLIGOPEPTIDES; THROMBIN; THROMBOPHLEBITIS;

EID: 0032997963     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008987211850     Document Type: Article

References (21)

1. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933-938.
2. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: A statement for healthcare professionals. Circulation 1996;93:2212-2245.
3. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1861-1828.
4. Pearson SD, Lee TH, McCabe-Hassan S, Dorsey JL, Goldhaber SZ. A critical pathway to treat proximal lower-extremity deep vein thrombosis. Am J Med 1995;100:283-289.
5. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1997;75:12B-7B.
6. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994;90:1522-1536.
7. Philippides GJ, Loscalzo J. Potential advantages of directacting thrombin inhibitors. Cor Art Dis 1996;7:497-507.
8. Finkie C, St-Pierre A, Leblond L, Deschenes I, DiMaio J, Winocour PD. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis; comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost 1998;79:431-438.
9. DiMaio J, Gibbs B, Lefebvre J, Konishi Y, Munn D, Yue S. Synthesis of a homologous series of ketomethylene arginyl pseudodipeptides and application to low molecular weight hirudin-like thrombin inhibitors. J Med Chem 1992;35: 3331-3341.
10. Sudo Y, Lucchesi BR. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: A comparison with heparin. J Cardiovasc Pharmacol 1996;27: 545-555.
11. DiMaio J, Winocour PD, Leblond L, Saifeddine M, Laniyonu A, Hollenberg MD. Thrombin inhibitors and thrombin receptor agonists/antagonists. Perspectives in receptor research. Perspect Receptor Res 1996;24:271-289.
12. Buchanan MR, Brister SJ, Finkle C, DiMaio J, Winocour PD. Inhibition of thrombin generation and platelet activation during cardiopulmonary bypass (CPB) in pigs. Haemostasis 1996;26:131.
13. Catella-Lawson F. Direct thrombin inhibitors in cardiovascular disease. Cor Art Dis 1997;8:105-111.
14. Turpie AGG, Weitz JI, Hirsh J. Advances in antithrombotic therapy: Novel agents. Thromb Haemost 1995;74:565-571.
15. Weitz J. New anticoagulant strategies. Drug 1994;48: 485-497.
16. Hermann JP, Kutryk MJB, Serruys PW. Clinical trials of direct thrombin inhibitors during invasive procedures. Thromb Haemost 1997;78:367-376.
17. White HD. Thrombin hypothesis: The TIMI 9B and GUSTO IIB trials have successfully disproven/proven the thrombin hypothesis. J Thrombo Thromboly 1997;4:317-319.
18. Ginsberg JS, Nurmohamed MT, Gent M, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994;90:2385-2389.
19. Eriksson BL, Kalebo P, Ekman S, Lindbratt S, Kerry R, Close P. Direct thrombin inhibition with Rec-hirudin CGP39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994;72: 227-231.
20. Verstraete M. Direct thrombin inhibitors: Appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997;78:357-363.
21. Rebello SS, Miller B, Basler GC, Lucchesi BR. CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol 1997;29:240-249.